Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Akt activation correlates with adverse outcome in tongue cancer.
Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Massarelli E, et al. Cancer. 2005 Dec 1;104(11):2430-6. doi: 10.1002/cncr.21476. Cancer. 2005. PMID: 16245318 Free article.
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer.
Ramisetty S, Kulkarni P, Bhattacharya S, Nam A, Singhal SS, Guo L, Mirzapoiazova T, Mambetsariev B, Mittan S, Malhotra J, Pisick E, Subbiah S, Rajurkar S, Massarelli E, Salgia R, Mohanty A. Ramisetty S, et al. Among authors: massarelli e. J Clin Med. 2023 Jan 11;12(2):599. doi: 10.3390/jcm12020599. J Clin Med. 2023. PMID: 36675528 Free PMC article.
Phase II Trial of Lung Chemoembolization.
Boas FE, Salgia R, Waddington T, Massarelli E, Park JJ, Kessler J, Frankel P, Alexander ES, Solomon SB. Boas FE, et al. Among authors: massarelli e. J Vasc Interv Radiol. 2023 Dec;34(12):2090-2092. doi: 10.1016/j.jvir.2023.08.006. Epub 2023 Aug 21. J Vasc Interv Radiol. 2023. PMID: 37611799 Free PMC article. Clinical Trial. No abstract available.
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR, Mambetsariev I, Lu KH, Wong CW, Duche A, Beuttler R, Fricke J, Pharoan R, Arvanitis L, Eftekhari Z, Amini A, Koczywas M, Massarelli E, Roosan MR, Salgia R. Sayer MR, et al. Among authors: massarelli e. Front Oncol. 2023 Feb 13;13:1064169. doi: 10.3389/fonc.2023.1064169. eCollection 2023. Front Oncol. 2023. PMID: 36860308 Free PMC article.
Integration of artificial intelligence in lung cancer: Rise of the machine.
Ladbury C, Amini A, Govindarajan A, Mambetsariev I, Raz DJ, Massarelli E, Williams T, Rodin A, Salgia R. Ladbury C, et al. Among authors: massarelli e. Cell Rep Med. 2023 Feb 21;4(2):100933. doi: 10.1016/j.xcrm.2023.100933. Epub 2023 Feb 3. Cell Rep Med. 2023. PMID: 36738739 Free PMC article. Review.
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, Guo L, Cho H, Li A, Behal A, Mirzapoiazova T, Massarelli E, Koczywas M, Arvanitis LD, Walser T, Villaflor V, Hamilton S, Mambetsariev I, Sattler M, Nasser MW, Jain M, Batra SK, Soldi R, Sharma S, Fakih M, Mohanty SK, Mainan A, Wu X, Chen Y, He Y, Chou TF, Roy S, Orban J, Kulkarni P, Salgia R. Mohanty A, et al. Among authors: massarelli e. Sci Adv. 2023 Oct 13;9(41):eade3816. doi: 10.1126/sciadv.ade3816. Epub 2023 Oct 13. Sci Adv. 2023. PMID: 37831779 Free PMC article.
123 results